mesoridazine has been researched along with debrisoquin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Hammarlund-Udenaes, M; Hedberg, A; Lidén, A; Movin, G; Nordin, C; Ring, H; Sjöqvist, F; von Bahr, C | 1 |
| Berecz, R; de la Rubia, A; Dorado, P; Llerena, A; Peñas-Lledó, EM | 1 |
2 trial(s) available for mesoridazine and debrisoquin
| Article | Year |
|---|---|
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
Topics: Adult; Antidepressive Agents; Debrisoquin; Humans; Hydroxylation; Male; Mesoridazine; Phenothiazines; Phenotype; Thioridazine | 1991 |
No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP1A2; Debrisoquin; Dose-Response Relationship, Drug; Genotype; Humans; Mental Disorders; Mesoridazine; Phenothiazines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Smoking; Thioridazine | 2007 |
1 other study(ies) available for mesoridazine and debrisoquin
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |